Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, turoctocog alfa (NovoEight®) cannot be endorsed for use within NHS Wales for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). |
||
|
||
Medicine details |
||
| Medicine name | turoctocog alfa (NovoEight®) | |
| Formulation | 250 units powder and solvent for solution for injection, 500 units powder and solvent for solution for injection, 1000 units powder and solvent for solution for injection, 1500 units powder and solvent for solution for injection, 2000 units powder and solvent for solution for injection, 3000 units powder and solvent for solution for injection | |
| Reference number | 1634 | |
| Company | Novo Nordisk Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 07/05/2014 | |
| Date of issue | 08/05/2014 | |